Compounds, compositions, and methods
US11111235B2 · kind B2 · utility
3Cited by
6References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2020 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Mar 13, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.